HIV/AIDS

Infectious Disease · 7 drugs · 4 indications

Competitive Landscape (7 drugs)
DrugCompanyMechanismModalityRouteStage
ClesrovimabMRKRSV F-protein neutralizingAntibodyIMFILED
BIC/LENGILDIntegrase strand transfer inhibitor (INSTI)Small moleculePOPHASE3
Lenacapavir + IslatravirMRK, GILDCapsid inhibitorSmall moleculePOPHASE3
IsentressMRKIntegrase inhibitorSmall moleculePOAPPROVED
BiktarvyGILDIntegrase strand transfer inhibitor (INSTI)Small moleculePOAPPROVED
DescovyGILDNucleotide reverse transcriptase inhibitor (NtRTI)Small moleculePOAPPROVED
SunlencaGILDCapsid inhibitorSmall moleculeSCAPPROVED
Indications (4)
RSV Prevention
Clesrovimab FILED
HIV-1 Infection
Isentress APPROVED
HIV-1 treatment
Biktarvy APPROVEDDescovy APPROVEDSunlenca APPROVEDBIC/LEN PHASE3Lenacapavir + Islatravir PHASE3
HIV-1 PrEP
Descovy APPROVEDSunlenca APPROVED
Upcoming Catalysts
ISL/LEN - HIV Treatment - Ph3 - Topline (ISLEND-1/2)CLINICAL
GILDH1 2026
BIC/LEN - HIV Treatment - FDA FilingREGULATORY
GILDH1 2026
Lenacapavir PrEP - Global RolloutCOMMERCIAL
GILD2026
Sunlenca + bNAbs - HIV Treatment - Ph3 InitiationCLINICAL
GILDH2 2026
Islatravir - HIV - Ph3 - UpdatesCLINICAL
MRK2026
Data from Supabase · Updated 2026-03-24